Financhill
Sell
24

BIOLQ Quote, Financials, Valuation and Earnings

Last price:
$0.0100
Seasonality move :
-6.46%
Day range:
$0.0089 - $0.0110
52-week range:
$0.0040 - $0.2570
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.00x
P/B ratio:
--
Volume:
122.4K
Avg. volume:
102.5K
1-year change:
-93.38%
Market cap:
$326.4K
Revenue:
$49.2M
EPS (TTM):
-$2.04

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
BIOLQ
Biolase
$13.5M -$0.01 3.78% -99.71% $1.2000
ALGN
Align Technology
$999.2M $2.45 -1.71% 44.8% $254.64
MLSS
Milestone Scientific
$2.7M -$0.01 17.38% -66.67% --
NVST
Envista Holdings
$645.9M $0.22 -2.29% 51.15% $21.33
SONX
Sonendo
-- -- -- -- --
XRAY
Dentsply Sirona
$920.3M $0.43 -10.43% 232.77% $20.20
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
BIOLQ
Biolase
$0.0089 $1.2000 $326.4K -- $0.00 0% 0.00x
ALGN
Align Technology
$166.20 $254.64 $12.2B 29.63x $0.00 0% 3.12x
MLSS
Milestone Scientific
$0.93 -- $72.1M -- $0.00 0% 8.17x
NVST
Envista Holdings
$16.65 $21.33 $2.9B -- $0.00 0% 1.15x
SONX
Sonendo
-- -- -- -- $0.00 0% --
XRAY
Dentsply Sirona
$15.33 $20.20 $3.1B -- $0.16 4.18% 0.82x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
BIOLQ
Biolase
142.17% 1.859 714.45% 0.23x
ALGN
Align Technology
-- 2.453 -- 1.02x
MLSS
Milestone Scientific
-- 2.706 -- 1.42x
NVST
Envista Holdings
32.21% 1.056 41.98% 1.63x
SONX
Sonendo
-- 0.000 -- --
XRAY
Dentsply Sirona
52.37% 0.344 56.57% 0.55x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
BIOLQ
Biolase
$4.4M -$695K -129.74% -21668.17% -7.48% -$4.5M
ALGN
Align Technology
$696.9M $177.1M 11.12% 11.12% 17.79% $263.1M
MLSS
Milestone Scientific
$1.8M -$1.5M -61.33% -61.33% -58.44% -$973.9K
NVST
Envista Holdings
$372.5M $67.7M -22.7% -32.33% 7.11% $123.8M
SONX
Sonendo
-- -- -- -- -- --
XRAY
Dentsply Sirona
$446M $9M -18.42% -32.39% -56.02% $36M

Biolase vs. Competitors

  • Which has Higher Returns BIOLQ or ALGN?

    Align Technology has a net margin of -13.16% compared to Biolase's net margin of 10.43%. Biolase's return on equity of -21668.17% beat Align Technology's return on equity of 11.12%.

    Company Gross Margin Earnings Per Share Invested Capital
    BIOLQ
    Biolase
    40.39% -$0.04 $12.4M
    ALGN
    Align Technology
    70.03% $1.39 $3.9B
  • What do Analysts Say About BIOLQ or ALGN?

    Biolase has a consensus price target of $1.2000, signalling upside risk potential of 22321.53%. On the other hand Align Technology has an analysts' consensus of $254.64 which suggests that it could grow by 53.21%. Given that Biolase has higher upside potential than Align Technology, analysts believe Biolase is more attractive than Align Technology.

    Company Buy Ratings Hold Ratings Sell Ratings
    BIOLQ
    Biolase
    1 1 0
    ALGN
    Align Technology
    9 5 0
  • Is BIOLQ or ALGN More Risky?

    Biolase has a beta of 0.817, which suggesting that the stock is 18.311% less volatile than S&P 500. In comparison Align Technology has a beta of 1.687, suggesting its more volatile than the S&P 500 by 68.738%.

  • Which is a Better Dividend Stock BIOLQ or ALGN?

    Biolase has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Align Technology offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biolase pays -- of its earnings as a dividend. Align Technology pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BIOLQ or ALGN?

    Biolase quarterly revenues are $10.9M, which are smaller than Align Technology quarterly revenues of $995.2M. Biolase's net income of -$1.4M is lower than Align Technology's net income of $103.8M. Notably, Biolase's price-to-earnings ratio is -- while Align Technology's PE ratio is 29.63x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biolase is 0.00x versus 3.12x for Align Technology. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BIOLQ
    Biolase
    0.00x -- $10.9M -$1.4M
    ALGN
    Align Technology
    3.12x 29.63x $995.2M $103.8M
  • Which has Higher Returns BIOLQ or MLSS?

    Milestone Scientific has a net margin of -13.16% compared to Biolase's net margin of -58.13%. Biolase's return on equity of -21668.17% beat Milestone Scientific's return on equity of -61.33%.

    Company Gross Margin Earnings Per Share Invested Capital
    BIOLQ
    Biolase
    40.39% -$0.04 $12.4M
    MLSS
    Milestone Scientific
    73.05% -$0.02 $7.2M
  • What do Analysts Say About BIOLQ or MLSS?

    Biolase has a consensus price target of $1.2000, signalling upside risk potential of 22321.53%. On the other hand Milestone Scientific has an analysts' consensus of -- which suggests that it could grow by 129.66%. Given that Biolase has higher upside potential than Milestone Scientific, analysts believe Biolase is more attractive than Milestone Scientific.

    Company Buy Ratings Hold Ratings Sell Ratings
    BIOLQ
    Biolase
    1 1 0
    MLSS
    Milestone Scientific
    0 0 0
  • Is BIOLQ or MLSS More Risky?

    Biolase has a beta of 0.817, which suggesting that the stock is 18.311% less volatile than S&P 500. In comparison Milestone Scientific has a beta of 1.409, suggesting its more volatile than the S&P 500 by 40.929%.

  • Which is a Better Dividend Stock BIOLQ or MLSS?

    Biolase has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Milestone Scientific offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biolase pays -- of its earnings as a dividend. Milestone Scientific pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BIOLQ or MLSS?

    Biolase quarterly revenues are $10.9M, which are larger than Milestone Scientific quarterly revenues of $2.5M. Biolase's net income of -$1.4M is higher than Milestone Scientific's net income of -$1.5M. Notably, Biolase's price-to-earnings ratio is -- while Milestone Scientific's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biolase is 0.00x versus 8.17x for Milestone Scientific. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BIOLQ
    Biolase
    0.00x -- $10.9M -$1.4M
    MLSS
    Milestone Scientific
    8.17x -- $2.5M -$1.5M
  • Which has Higher Returns BIOLQ or NVST?

    Envista Holdings has a net margin of -13.16% compared to Biolase's net margin of 0.18%. Biolase's return on equity of -21668.17% beat Envista Holdings's return on equity of -32.33%.

    Company Gross Margin Earnings Per Share Invested Capital
    BIOLQ
    Biolase
    40.39% -$0.04 $12.4M
    NVST
    Envista Holdings
    57.05% $0.01 $4.3B
  • What do Analysts Say About BIOLQ or NVST?

    Biolase has a consensus price target of $1.2000, signalling upside risk potential of 22321.53%. On the other hand Envista Holdings has an analysts' consensus of $21.33 which suggests that it could grow by 28.13%. Given that Biolase has higher upside potential than Envista Holdings, analysts believe Biolase is more attractive than Envista Holdings.

    Company Buy Ratings Hold Ratings Sell Ratings
    BIOLQ
    Biolase
    1 1 0
    NVST
    Envista Holdings
    3 10 1
  • Is BIOLQ or NVST More Risky?

    Biolase has a beta of 0.817, which suggesting that the stock is 18.311% less volatile than S&P 500. In comparison Envista Holdings has a beta of 1.326, suggesting its more volatile than the S&P 500 by 32.59%.

  • Which is a Better Dividend Stock BIOLQ or NVST?

    Biolase has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Envista Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biolase pays -- of its earnings as a dividend. Envista Holdings pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BIOLQ or NVST?

    Biolase quarterly revenues are $10.9M, which are smaller than Envista Holdings quarterly revenues of $652.9M. Biolase's net income of -$1.4M is lower than Envista Holdings's net income of $1.2M. Notably, Biolase's price-to-earnings ratio is -- while Envista Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biolase is 0.00x versus 1.15x for Envista Holdings. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BIOLQ
    Biolase
    0.00x -- $10.9M -$1.4M
    NVST
    Envista Holdings
    1.15x -- $652.9M $1.2M
  • Which has Higher Returns BIOLQ or SONX?

    Sonendo has a net margin of -13.16% compared to Biolase's net margin of --. Biolase's return on equity of -21668.17% beat Sonendo's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    BIOLQ
    Biolase
    40.39% -$0.04 $12.4M
    SONX
    Sonendo
    -- -- --
  • What do Analysts Say About BIOLQ or SONX?

    Biolase has a consensus price target of $1.2000, signalling upside risk potential of 22321.53%. On the other hand Sonendo has an analysts' consensus of -- which suggests that it could fall by --. Given that Biolase has higher upside potential than Sonendo, analysts believe Biolase is more attractive than Sonendo.

    Company Buy Ratings Hold Ratings Sell Ratings
    BIOLQ
    Biolase
    1 1 0
    SONX
    Sonendo
    0 0 0
  • Is BIOLQ or SONX More Risky?

    Biolase has a beta of 0.817, which suggesting that the stock is 18.311% less volatile than S&P 500. In comparison Sonendo has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock BIOLQ or SONX?

    Biolase has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sonendo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biolase pays -- of its earnings as a dividend. Sonendo pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BIOLQ or SONX?

    Biolase quarterly revenues are $10.9M, which are larger than Sonendo quarterly revenues of --. Biolase's net income of -$1.4M is higher than Sonendo's net income of --. Notably, Biolase's price-to-earnings ratio is -- while Sonendo's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biolase is 0.00x versus -- for Sonendo. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BIOLQ
    Biolase
    0.00x -- $10.9M -$1.4M
    SONX
    Sonendo
    -- -- -- --
  • Which has Higher Returns BIOLQ or XRAY?

    Dentsply Sirona has a net margin of -13.16% compared to Biolase's net margin of -47.51%. Biolase's return on equity of -21668.17% beat Dentsply Sirona's return on equity of -32.39%.

    Company Gross Margin Earnings Per Share Invested Capital
    BIOLQ
    Biolase
    40.39% -$0.04 $12.4M
    XRAY
    Dentsply Sirona
    49.28% -$2.16 $4.1B
  • What do Analysts Say About BIOLQ or XRAY?

    Biolase has a consensus price target of $1.2000, signalling upside risk potential of 22321.53%. On the other hand Dentsply Sirona has an analysts' consensus of $20.20 which suggests that it could grow by 31.77%. Given that Biolase has higher upside potential than Dentsply Sirona, analysts believe Biolase is more attractive than Dentsply Sirona.

    Company Buy Ratings Hold Ratings Sell Ratings
    BIOLQ
    Biolase
    1 1 0
    XRAY
    Dentsply Sirona
    2 11 0
  • Is BIOLQ or XRAY More Risky?

    Biolase has a beta of 0.817, which suggesting that the stock is 18.311% less volatile than S&P 500. In comparison Dentsply Sirona has a beta of 0.976, suggesting its less volatile than the S&P 500 by 2.383%.

  • Which is a Better Dividend Stock BIOLQ or XRAY?

    Biolase has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Dentsply Sirona offers a yield of 4.18% to investors and pays a quarterly dividend of $0.16 per share. Biolase pays -- of its earnings as a dividend. Dentsply Sirona pays out -13.85% of its earnings as a dividend.

  • Which has Better Financial Ratios BIOLQ or XRAY?

    Biolase quarterly revenues are $10.9M, which are smaller than Dentsply Sirona quarterly revenues of $905M. Biolase's net income of -$1.4M is higher than Dentsply Sirona's net income of -$430M. Notably, Biolase's price-to-earnings ratio is -- while Dentsply Sirona's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biolase is 0.00x versus 0.82x for Dentsply Sirona. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BIOLQ
    Biolase
    0.00x -- $10.9M -$1.4M
    XRAY
    Dentsply Sirona
    0.82x -- $905M -$430M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Qualcomm Stock: 5G Leader at a Bargain Price?
Qualcomm Stock: 5G Leader at a Bargain Price?

Chip giant QUALCOMM Incorporated (NASDAQ:QCOM) was the ultimate chip company…

What Is Buffett Buying and Selling Now?
What Is Buffett Buying and Selling Now?

In Q4 of last year, Warren Buffett made a few…

3 Safest Stocks to Buy Now
3 Safest Stocks to Buy Now

With the S&P 500 now in correction and stocks selling…

Stock Ideas

Buy
52
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Buy
56
Is NVDA Stock a Buy?

Market Cap: $3T
P/E Ratio: 41x

Buy
51
Is MSFT Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 33x

Alerts

Buy
59
GRRR alert for Mar 15

Gorilla Technology Group [GRRR] is up 29.72% over the past day.

Sell
49
SMTC alert for Mar 15

Semtech [SMTC] is up 21.28% over the past day.

Buy
62
PLPC alert for Mar 15

Preformed Line Products [PLPC] is up 17.38% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock